1. Home
  2. SWVL vs CLGN Comparison

SWVL vs CLGN Comparison

Compare SWVL & CLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Swvl Holdings Corp

SWVL

Swvl Holdings Corp

HOLD

Current Price

$1.37

Market Cap

15.6M

ML Signal

HOLD

Logo CollPlant Biotechnologies Ltd

CLGN

CollPlant Biotechnologies Ltd

HOLD

Current Price

$0.71

Market Cap

18.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SWVL
CLGN
Founded
2017
2004
Country
United Arab Emirates
Israel
Employees
284
N/A
Industry
Business Services
Industrial Specialties
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.6M
18.4M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
SWVL
CLGN
Price
$1.37
$0.71
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$11.00
AVG Volume (30 Days)
15.6K
27.9K
Earning Date
04-02-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$1,596.12
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.32
$0.50
52 Week High
$4.99
$4.98

Technical Indicators

Market Signals
Indicator
SWVL
CLGN
Relative Strength Index (RSI) 39.55 50.41
Support Level $1.34 $0.58
Resistance Level $3.83 $0.73
Average True Range (ATR) 0.07 0.07
MACD -0.00 0.03
Stochastic Oscillator 22.41 48.11

Price Performance

Historical Comparison
SWVL
CLGN

About SWVL Swvl Holdings Corp

Swvl Holdings Corp is a technology-driven mobility company that aims to provide reliable, safe, cost-effective and environmentally responsible mass transit solutions. It provides mobility solutions for enterprises and government and individual commuters across-multiple markets with clients such as Amazon, Bosch, E&, P&G and Siemens. The Company operates in Egypt, Saudi Arabia and the UAE.

About CLGN CollPlant Biotechnologies Ltd

CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.

Share on Social Networks: